Chemogenomics approaches to novel target discovery

References

• Schreiber SL. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem.6(8), 1127–1152 (1998).
   PubMed Web of Science ®Google Scholar
• Harris CJ, Stevens AP. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov. Today11(19–20), 880–888 (2006).
   PubMed Web of Science ®Google Scholar
• Huang Y, Sadee W. Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. Drug Discov. Today8(8), 356–363 (2003).
   PubMed Web of Science ®Google Scholar
• Smukste I, Stockwell BR. Advances in chemical genetics. Annu. Rev. Genomics Hum. Genet.6, 261–286 (2005).
   PubMed Web of Science ®Google Scholar
• Mestres J. Computational chemogenomics approaches to systematic knowledge-based drug discovery. Curr. Opin Drug Discov. Devel.7(3), 304–313 (2004).
   Google Scholar
• MDL Comprehensive Medicinal Chemistry (CMC-3D) Database: MDL Information Systems Inc., San Leandro, CA. Pergamon Press, NY, USA. 6 (1990).
   Google Scholar
• World Drug Index. Derwent Information Ltd, London, UK.
   Google Scholar
• Olah M, Bologa C, Oprea TI. An automated PLS search for biologically relevant QSAR descriptors. J. Comput. Aided Mol. Des.18(7–9), 437–449 (2004).
   PubMed Web of Science ®Google Scholar
• Strausberg RL, Schreiber SL. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science300(5617), 294–295 (2003).
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Myers TG, O’Connor PM et al. An information-intensive approach to the molecular pharmacology of cancer. Science275(5298), 343–349 (1997).
   PubMed Web of Science ®Google Scholar
• Roth BL, Kroeze WK, Patel S, Lopez E. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist6, 252–262 (2000).
   Web of Science ®Google Scholar
• Bredel M, Jacoby E. Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat. Rev. Genet.5(4), 262–275 (2004).
   PubMed Web of Science ®Google Scholar
• Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat. Biotechnol.24(7), 805–815 (2006).
   PubMed Web of Science ®Google Scholar
• Caron PR, Mullican MD, Mashal RD, Wilson KP, Su MS, Murcko MA. Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol.5(4), 464–470 (2001).
   PubMed Web of Science ®Google Scholar
• Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet.1(2), 116–125 (2000).
   PubMed Web of Science ®Google Scholar
• Stockwell BR. Frontiers in chemical genetics. Trends Biotechnol.18(11), 449–455 (2000).
   PubMed Web of Science ®Google Scholar
• Bishop AC, Buzko O, Shokat KM. Magic bullets for protein kinases. Trends Cell Biol.11(4), 167–172 (2001).
   PubMed Web of Science ®Google Scholar
• Jacoby E. Chemogenomics, Knowledge-Based Approaches to Drug Discovery. Imperial College Press, London, UK (2006).
   Google Scholar
• Deveraux QL, Aza-Blanc P, Wagner KW, Bauerschlag D, Cooke MP, Hampton GM. Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. Semin. Cancer Biol.13(4), 293–300 (2003).
   PubMed Web of Science ®Google Scholar
• Zaarur N, Gabai VL, Porco JA Jr, Calderwood S, Sherman MY. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res.66(3), 1783–1791 (2006).
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer5, 689–698 (2005).
   PubMed Web of Science ®Google Scholar
• Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP. Identification of modulators of TRAILHinduced apoptosis via RNAiHbased phenotypic screening. Mol. Cell12(3), 627–637 (2003).
   PubMed Web of Science ®Google Scholar
• Lackner MR, Kindt RM, Carroll PM et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell7, 325–336 (2005).
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature391(6669), 806–811 (1998).
   PubMed Web of Science ®Google Scholar
• Sachse C, Echeverri CJ. Oncology studies using siRNA libraries: the dawn of RNAi-based genomics. Oncogene23(51), 8384–9391 (2004).
   PubMed Web of Science ®Google Scholar
• Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knock-down in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl Acad. Sci. USA100(4), 1844–1848 (2003).
   PubMed Web of Science ®Google Scholar
• Alisky JM, Davidson BL. Towards therapy using RNA interference.Am. J. Pharmacogenomics4(1), 45–51 (2004).
   Google Scholar
• Kim TK. Chemical genomics and medicinal systems biology: chemical control of genomic networks in human systems biology for innovative medicine. J. Biochem. Mol. Biol.37(1), 53–58 (2004).
   Google Scholar
• Hartman JL, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science291(5506) 1001–1004 (2001).
   PubMed Web of Science ®Google Scholar
• Samani AA, Yakar S, Leroith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev.28(1), 20–47 (2007).
   PubMed Web of Science ®Google Scholar
• Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Invasion is a genetic program regulated by transcription factors. Curr. Opin Genet. Dev.16(1), 65–70 (2006).
   PubMedGoogle Scholar
• Syed V, Zhang X, Lau KM, Cheng R, Mukherjee K, Ho SM. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene24(55), 8128–8143 (2005).
   PubMed Web of Science ®Google Scholar
• Marsh I. Easing the chemistry bottleneck: careers in high-throughput chemistry. Nat. Rev. Drug Discov.1(11), 925 (2002).
   Google Scholar
• Zarraga IG, Schwarz ER. Coxibs and heart disease: what we have learned and what else we need to know. J. Am. Coll. Cardiol.49(1), 1–14 (2007).
   PubMed Web of Science ®Google Scholar
• Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol.25(2), 197–206 (2007).
   PubMed Web of Science ®Google Scholar
• Mestres J, Martin-Couce L, Gregori-Puigjane E, Cases M, Boyer S. Ligand-based approach to in silico pharmacology: nuclear receptor profiling. J. Chem. Inf. Model.46(6), 2725–2736 (2006).
   PubMed Web of Science ®Google Scholar
• Cleves AE, Jain AN. Robust ligand-based modeling of the biological targets of known drugs. J. Med. Chem.49(10), 2921–2938 (2006).
   PubMed Web of Science ®Google Scholar
• MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol.7(6), 591–600 (2005).
   PubMed Web of Science ®Google Scholar
• Bartz SR, Zhang Z, Burchard J et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol.26(24), 9377–9386 (2006).
   PubMed Web of Science ®Google Scholar
• Jaeschke A, Karasarides M, Ventura JJ et al. JNK2 is a positive regulator of the c-Jun transcription factor. Mol. Cell23(6), 899–911 (2006).
   PubMed Web of Science ®Google Scholar
• Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol.2(12), 689–700 (2006).
   PubMed Web of Science ®Google Scholar
• Wishart MJ, Denu JM, Williams JA, Dixon JE. A single mutation converts a novel phosphotyrosine binding domain into a dual-specificity phosphatase. J. Biol. Chem.270(45), 26782–26785 (1995).
   PubMedGoogle Scholar
• Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin. Cancer Res.10(12 Pt 2), S4210–S4214 (2004).
   PubMed Web of Science ®Google Scholar
• Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene22(56), 9030–9040 (2003).
   PubMed Web of Science ®Google Scholar
• Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet.30(3), 285–289 (2002).
   PubMed Web of Science ®Google Scholar
• Ewart-Toland A, Briassouli P, de Koning JP et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet.34(4), 403–412 (2003).
   PubMed Web of Science ®Google Scholar
• Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res.67(1), 339–345 (2007).
   PubMed Web of Science ®Google Scholar
• Bishop AC, Buzko O, Shokat KM. Magic bullets for protein kinases. Trends Cell Biol.11(4), 167–172 (2001).
   PubMed Web of Science ®Google Scholar
• Bishop AC, Ubersax JA, Petsch DT et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature407(6802), 395–401 (2000).
   PubMed Web of Science ®Google Scholar
• Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell15(5), 713–725 (2004).
   PubMed Web of Science ®Google Scholar
• Lin X, Ruan X, Anderson MG et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res.33(14), 4527–4535 (2005).
   PubMed Web of Science ®Google Scholar
• Kraynack BA, Baker BF. Small interfering RNAs containing full 2´-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA12(1), 163–176 (2006).
   PubMed Web of Science ®Google Scholar
• Ross-Macdonald P. Forward in reverse: how reverse genetics complements chemical genetics. Pharmacogenomics6(4), 429–434 (2005).
   Google Scholar
• Evanko D. Systems biology for beginners. Nat. Methods3(12), 964–965 (2006).
   Google Scholar
• Gilbert D, Fuss H, Gu X et al. Computational methodologies for modelling, analysis and simulation of signalling networks. Brief Bioinform.7(4), 339–353 (2006).
   Google Scholar
• Moffat J, Grueneberg DA, Yang X et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell124(6), 1283–1298 (2006).
   PubMed Web of Science ®Google Scholar
• Ngo VN, Davis RE, Lamy L et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature441(7089), 106–110 (2006).
   PubMed Web of Science ®Google Scholar
• Wu MT, Wu RH, Hung CF, Cheng TL, Tsai WH, Chang WT. Simple and efficient DNA vector-based RNAi systems in mammalian cells. Biochem. Biophys. Res. Commun.330(1), 53–59 (2005).
   Google Scholar
• Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR–ABL-positive cells. Blood90(9), 3691–3698 (1997).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med.344(14), 1038–1042 (2001).
   PubMed Web of Science ®Google Scholar